Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.

News | Peripheral Artery Disease (PAD)

Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia

November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral ...

November 15, 2022

When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.

News | Heart Failure

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

November 14, 2022

Less complex heart patients may benefit, but not without risk

News | Pediatric Cardiology

Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery

November 14, 2022 — For more than four decades, doctors have been split on whether giving steroids during a pediatric ...

November 14, 2022

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022

The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.

News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

November 14, 2022

Investigators Compared AFib Patients Treated with Catheter Ablation to Those Treated with Anti-arrhythmic Drugs Only

News | Atrial Fibrillation

Study Finds Catheter Ablation Significantly Lowers Risk of Dementia in Patients with Atrial Fibrillation

November 10, 2022 — Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

November 10, 2022

When the SARS-CoV-2 protein Nsp6 is made in a fruit fly heart (center), the heart has structural defects compared to a normal heart without the viral protein (left). When fruit fly hearts with the viral Nsp6 protein are given the metabolism changing drug 2DG (right), the hearts begin to look more normal than the ones with the viral protein that do not have the drug. Image courtesy of Zhe Han at UMSOM

News | Coronavirus (COVID-19)

How a SARS-CoV-2 Virus Protein Damages the Heart

November 10, 2022 — Researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease ...

November 10, 2022

Findings from the BEST-CLI trial presented at the American Heart Association Scientific Sessions (AHA2022) indicate optimal treatment for patients with limb-threatening ischemia.

News | AHA

BEST-CLI Clinical Trial Focuses on Optimal Treatment for Limb-Threatening Ischemia

November 10, 2022 – Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best ...

November 10, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Heart Failure

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

November 09, 2022

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022

New genomic therapies for cardiovascular disease are reaching the clinical trial stage, according to moderators of a session presented at the American Heart Association Annual Scientific Session (AHA2022).

News | AHA

Progress Reported on Clinical Trials of Genomic Profiling for Cardiovascular Disease at AHA 2022

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

November 08, 2022

Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz

News | AHA

TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

November 08, 2022

Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis

News | AHA

Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

November 08, 2022

Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications

News | AHA

Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

November 08, 2022

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment

News | AHA

Late-Breaking Data Demonstrate AHA/ACC Guideline-Directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results ...

November 07, 2022